In a short but sweet filing with the Securities and Exchange Commission, BioMimetic Therapeutics officials this week said they haven't yet heard back from the Food and Drug Administration about the hurdles they'll have to clear to bring their anticipated Augement Bone Graft product to the U.S. market.

Since the FDA is not bound by a specific deadline for communicating the Company’s formal post-panel requirements, the Company believes that the absence of a letter at this time should not be construed as suggestive of the FDA’s position on the PMA.

SEE ALSO: BioMimetic shares spike after FDA hearing from July